Affimed N.V., a clinical stage biopharmaceutical company committed to improving patient outcomes through the power of the innate immune system, has announced that two abstracts from the Company’s innate cell engager program have been accepted for poster presentation at the American Association of Cancer Research (AACR) Annual Meeting 2019 in Atlanta, GA.
Affimed, founded in 2000, based in Heidelberg, Germany, engineers targeted immunotherapies. The company’s fit-for-purpose ROCK® platform allows innate immune engagers to be designed for specific patient populations. It is developing single and combination therapies to treat cancers.
AFM24 (EGFR/CD16A engager), in development for the treatment of patients with a variety of EGFR-expressing solid tumors, is designed to address limitations associated with other EGFR-targeting therapies, such as toxicities or resistances. Data highlighting the differentiating features of AFM24 will be presented, including toxicology studies demonstrating a favorable safety profile.
An adoptive immunotherapy approach with AFM13 (CD30/CD16A engager)-loaded cord blood-derived NK cells has recently been pre-clinically established and appears to be a promising approach to treating patients with relapsed/refractory CD30-positive malignancies. Further substantiating Affimed’s rationale for combining AFM13 with activated NK cell-based therapies, together with its collaboration partners from Washington University School of Medicine, Saint Louis, Missouri, Affimed will present data aimed at describing NK cell functional responses to tumor cells triggered via AFM13.